03.jpg

INNOVATION

Pipeline

OnQuality Pharmaceuticals is pioneering the field of targeted supportive cancer care. Our lead compound is an oncodermatology hand and foot ointment called OQL011, which is for the treatment of Hand-Foot Skin Reaction. It is being studied in a phase 2 clinical trial that is currently enrolling. We also have two promising assets that are currently in the pre-clinical stage and will enter clinical trials in the near future.  Additionally, we have two promising assets that are in the early discovery stage targeting oncogastroenterology conditions.

Therapeutic indication

Discovery

IND

Phase I

Phase II

Phase III

OQL011

VEGFR Inhibitor-induced hand-foot skin reaction

OQL023
EGFR Inhibitor-induced skin rash
OQL033
Chemotherapy-induced hand-foot syndrome
OQL041
EGFR inhibitor-induced diarrhea
OQL051
Chemotherapy-induced diarrhea